FindTrial
Sign In

Pantoprazole in Cisplatin Nephrotoxicity

Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04217512
Enrollment
60
Registered
2020-01-03
Start date
2019-05-01
Completion date
2030-12-30
Last updated
2020-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oncology

Brief summary

Pantoprazole in Cisplatin Nephrotoxicity

Detailed description

Pantoprazole in Cisplatin NephrotoxicityPantoprazole in Cisplatin Nephrotoxicity. Is it protective?

Interventions

DRUGPantoprazole low dose

Pantoprazole 0.6 mg/kg

DRUGPantoprazole high dose

Pantoprazole 1.6 mg\\kg

OTHERStandard hydration

Standard hydration alone

DRUGCisplatin

Cisplatin

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with head and neck cancer

Exclusion criteria

* GFR less than 59. * DM * Elevated liver enzymes more than 3 fold.

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with no renal toxicity6 monthsThe number of patients with no renal toxicity

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026